private:neuravi
|
2653498
|
Dec 3rd, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Dec 3rd, 2020 11:55AM
|
Dec 3rd, 2020 11:55AM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Dec 2nd, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Dec 2nd, 2020 02:16PM
|
Dec 2nd, 2020 02:16PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Dec 1st, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Dec 1st, 2020 01:45PM
|
Dec 1st, 2020 01:45PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Nov 30th, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Nov 29th, 2020 07:49PM
|
Nov 30th, 2020 02:37PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Nov 28th, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Nov 28th, 2020 03:25PM
|
Nov 28th, 2020 03:25PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Nov 27th, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Nov 27th, 2020 11:50AM
|
Nov 27th, 2020 11:50AM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Nov 26th, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Nov 26th, 2020 12:48PM
|
Nov 26th, 2020 12:48PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Nov 25th, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Nov 25th, 2020 06:20PM
|
Nov 25th, 2020 06:20PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Nov 24th, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Nov 24th, 2020 01:38PM
|
Nov 24th, 2020 01:38PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:neuravi
|
2653498
|
Nov 23rd, 2020 12:00AM
|
Neuravi
|
1.8K
|
12.00
|
Open
|
Medical Device
|
Nov 23rd, 2020 03:38PM
|
Nov 23rd, 2020 03:38PM
|
Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
|
Open
|
|
Open
|
|
|
|
|
|
|
Neuravi
|
Health Care
|
Pharmaceuticals & Biotechnology
|